herincar-pd1 cells
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02862028)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Epidermal growth factor receptor erbB1Immunity, passive
EGFR immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- herincar-pd1 cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02862028 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | Fudan University |
| NCT02873390 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | Ningbo Cancer Hospital, Ningbo No. 5 Hospital, Shanghai Cell Therapy Research Institute |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Ningbo Cancer Hospital | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Ningbo No. 5 Hospital | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Shanghai Cell Therapy Research Institute | Academic/Hospital | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1